Aurinia Pharmaceuticals Reports New Phase IIb Data

Aurinia Pharmaceuticals Reports New Phase IIb Data

Shares of Aurinia Pharmaceuticals Inc. were up over 5% in pre-market trading after it reported new remission data from its phase IIB AURA-LV (AURA) study in lupus nephritis (LN) The company said the data demonstrated that over the course of the 48-week trial, patients on voclosporin stayed in remission approximately twice as long as those in the control group. It said the differences were statistically significant versus the control arm, […]

Read More ˃